Adeela Kamal
YOU?
Author Swipe
View article: Combination of the Novel <scp>RAF</scp> Dimer Inhibitor Brimarafenib With the <scp>MEK</scp> Inhibitor Mirdametinib Is Effective Against <scp>NRAS</scp> Mutant Melanoma
Combination of the Novel <span>RAF</span> Dimer Inhibitor Brimarafenib With the <span>MEK</span> Inhibitor Mirdametinib Is Effective Against <span>NRAS</span> Mutant Melanoma Open
Metastatic melanoma, the most aggressive form of skin cancer, accounts for the majority of skin cancer‐related deaths. While targeted kinase inhibitors have improved outcomes for patients with BRAF‐mutated melanomas, their efficacy is ofte…
View article: Figure S1 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Figure S1 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
Figure S1 shows A) Fraction of transfected cells after re-expression of NF2 in HEK293 and NF2-mutant mesothelioma cell lines. The proliferation of NF2-mutant mesothelioma cell lines, but not the NF2 wild-type HEK293 cells, is suppressed by…
View article: Figure S3 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Figure S3 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
Figure S3 shows Heatmap of differential pathway analysis comparing the tumors of vehicle and SWTX-143-treated mice.
View article: Figure S2 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Figure S2 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
Figure S2 shows A) Heatmap showing YAP signature genes in vehicle and SWTX-143-treated kidney cancer cell line. B) Gene Set Enrichment Analysis of the YAP signature.
View article: Data from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Data from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
The Hippo pathway and its downstream effectors, the YAP and TAZ transcriptional coactivators, are deregulated in multiple different types of human cancer and are required for cancer cell phenotypes in vitro and in vivo, while largely dispe…
View article: Figure S4 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Figure S4 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
Figure S4 shows A) Immunofluorescence stainings of lung sections from mice with mesothelioma after 2 weeks after Adeno-Cre injection, stained for Vimentin (green) and Mesothelin (red). B) Picture of an H&E staining of a lung section from a…
View article: Supplementary Methods from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Supplementary Methods from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
X-ray specifications
View article: Data from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Data from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
The Hippo pathway and its downstream effectors, the YAP and TAZ transcriptional coactivators, are deregulated in multiple different types of human cancer and are required for cancer cell phenotypes in vitro and in vivo, while largely dispe…
View article: Figure S2 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Figure S2 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
Figure S2 shows A) Heatmap showing YAP signature genes in vehicle and SWTX-143-treated kidney cancer cell line. B) Gene Set Enrichment Analysis of the YAP signature.
View article: Figure S3 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Figure S3 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
Figure S3 shows Heatmap of differential pathway analysis comparing the tumors of vehicle and SWTX-143-treated mice.
View article: Supplementary Methods from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Supplementary Methods from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
X-ray specifications
View article: Figure S1 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Figure S1 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
Figure S1 shows A) Fraction of transfected cells after re-expression of NF2 in HEK293 and NF2-mutant mesothelioma cell lines. The proliferation of NF2-mutant mesothelioma cell lines, but not the NF2 wild-type HEK293 cells, is suppressed by…
View article: Figure S4 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
Figure S4 from A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
Figure S4 shows A) Immunofluorescence stainings of lung sections from mice with mesothelioma after 2 weeks after Adeno-Cre injection, stained for Vimentin (green) and Mesothelin (red). B) Picture of an H&E staining of a lung section from a…
View article: A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models
A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models Open
The Hippo pathway and its downstream effectors, the YAP and TAZ transcriptional coactivators, are deregulated in multiple different types of human cancer and are required for cancer cell phenotypes in vitro and in vivo, while largely dispe…
View article: Data from Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4
Data from Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4 Open
Antibody–drug conjugates (ADC) are used to selectively deliver cytotoxic agents to tumors and have the potential for increased clinical benefit to cancer patients. 5T4 is an oncofetal antigen overexpressed on the cell surface in many carci…
View article: Supplementary Data from Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4
Supplementary Data from Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4 Open
Supplementary Figure S1. Comparable internalization rates for 5T4_0108 and the 5T4-Tub ADC;Supplementary Figure S2. Affinity optimization improves in vitro cytotoxicity of a 5T4-ADC;Supplementary Figure S3. Induction of apoptosis by 5T4-PB…
View article: Data from Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4
Data from Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4 Open
Antibody–drug conjugates (ADC) are used to selectively deliver cytotoxic agents to tumors and have the potential for increased clinical benefit to cancer patients. 5T4 is an oncofetal antigen overexpressed on the cell surface in many carci…
View article: Supplementary Data from Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4
Supplementary Data from Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4 Open
Supplementary Figure S1. Comparable internalization rates for 5T4_0108 and the 5T4-Tub ADC;Supplementary Figure S2. Affinity optimization improves in vitro cytotoxicity of a 5T4-ADC;Supplementary Figure S3. Induction of apoptosis by 5T4-PB…
View article: A review of β-caryophyllene oxide for its pharmacological properties supported by in silico findings
A review of β-caryophyllene oxide for its pharmacological properties supported by in silico findings Open
Bicyclic sesquiterpene, β-caryophyllene oxide (BCO) is one of the major components of essential oil derived from aromatic plants. It is reported to possess several interesting pharmacological prospects. BCO’s ability to suppress a few sign…
View article: Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance
Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance Open
Although anti-tumor activities of type I interferons (IFNs) have been recognized for decades, the molecular mechanisms contributing to clinical response remain poorly understood. The complex functions of these pleiotropic cytokines include…
View article: The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins Open
A primary pathologic component of Alzheimer’s disease (AD) is the formation of neurofibrillary tangles composed of hyperphosphorylated tau (p-tau). Expediting the removal of these p-tau species may be a relevant therapeutic strategy. Here …
View article: Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4
Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4 Open
Antibody–drug conjugates (ADC) are used to selectively deliver cytotoxic agents to tumors and have the potential for increased clinical benefit to cancer patients. 5T4 is an oncofetal antigen overexpressed on the cell surface in many carci…